Lavipharm S.A (LAVI) - Cash Flow Conversion Efficiency

Latest as of December 2022: 0.013x

Based on the latest financial reports, Lavipharm S.A (LAVI) has a cash flow conversion efficiency ratio of 0.013x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€527.00K ≈ $616.12K USD) by net assets (€40.28 Million ≈ $47.09 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See LAVI net asset quality score to measure how much of total assets are equity-financed.

Lavipharm S.A - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how Lavipharm S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Lavipharm S.A to evaluate the quality of earnings relative to operating cash generation.

Lavipharm S.A Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Lavipharm S.A ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Amorepacific Corp Pref KO:090435	0.026x
Wanxiang Doneed Co Ltd SHG:600371	-0.012x
Bali Towerindo Sentra Tbk JK:BALI	0.048x
Albatron Technology Co Ltd TWO:5386	0.357x
Cadiz Inc NASDAQ:CDZI	-0.298x
Advanced Ceramic X TWO:3152	0.017x
TYC Brother Industrial Co Ltd TW:1522	0.061x
Shanghai Kaichuang Marine International Co Ltd SHG:600097	0.041x

Annual Cash Flow Conversion Efficiency for Lavipharm S.A (2014–2024)

The table below shows the annual cash flow conversion efficiency of Lavipharm S.A from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Lavipharm S.A.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€52.97 Million ≈ $61.92 Million	€4.64 Million ≈ $5.42 Million	0.088x	+1219.29%
2023-12-31	€42.77 Million ≈ $50.00 Million	€284.00K ≈ $332.03K	0.007x	-92.01%
2022-12-31	€40.28 Million ≈ $47.09 Million	€3.35 Million ≈ $3.91 Million	0.083x	+121.62%
2021-12-31	€-9.94 Million ≈ $-11.62 Million	€3.82 Million ≈ $4.46 Million	-0.384x	-65.91%
2020-12-31	€-12.30 Million ≈ $-14.38 Million	€2.85 Million ≈ $3.33 Million	-0.232x	-15.32%
2019-12-31	€-14.40 Million ≈ $-16.84 Million	€2.89 Million ≈ $3.38 Million	-0.201x	-176.84%
2018-12-31	€-19.53 Million ≈ $-22.83 Million	€1.42 Million ≈ $1.66 Million	-0.073x	+4.54%
2017-12-31	€-19.92 Million ≈ $-23.29 Million	€1.51 Million ≈ $1.77 Million	-0.076x	-299.17%
2016-12-31	€-31.82 Million ≈ $-37.21 Million	€606.00K ≈ $708.48K	-0.019x	-112.96%
2015-12-31	€-64.42 Million ≈ $-75.31 Million	€576.00K ≈ $673.40K	-0.009x	+81.60%
2014-12-31	€-48.96 Million ≈ $-57.24 Million	€2.38 Million ≈ $2.78 Million	-0.049x	--

About Lavipharm S.A

AT:LAVI Greece Drug Manufacturers - Specialty & Generic

Market Cap

$284.59 Million

€243.42 Million EUR

Market Cap Rank

#15021 Global

#41 in Greece

Share Price

€1.44

Change (1 day)

-2.31%

52-Week Range

€0.78 - €1.70

All Time High

€2.05